BAKER BROS. ADVISORS LP Q1 2021 Filing
Filed May 17, 2021
Portfolio Value
$23.1B
Holdings
126
Report Date
Q1 2021
Filing Type
13F-HR
All Holdings (126 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 101 | HRMYHarmony Biosciences Holdings, Inc. | 123,600 | $4.1B | 17.71% | |
| 102 | —TCR2 Therapeutics Inc. | 176,461 | $3.9B | 16.89% | |
| 103 | 1T7Tricida, Inc. | 729,300 | $3.9B | 16.73% | |
| 104 | AKROAkero Therapeutics, Inc. | 118,378 | $3.4B | 14.89% | |
| 105 | LEGNLegend Biotech Corporation | 115,626 | $3.4B | 14.55% | |
| 106 | —LogicBio Therapeutics, Inc. | 451,478 | $3.3B | 14.25% | |
| 107 | TARAProtara Therapeutics, Inc. | 199,671 | $3.1B | 13.63% | |
| 108 | XLRNAcceleron Pharma Inc. | 22,430 | $3.0B | 13.19% | |
| 109 | —Constellation Pharmaceuticals, Inc. | 114,735 | $2.7B | 11.64% | |
| 110 | —Idera Pharmaceuticals, Inc. | 2,047,180 | $2.7B | 11.54% | |
| 111 | AUTLAutolus Therapeutics plc | 461,726 | $2.6B | 11.47% | |
| 112 | —Chiasma, Inc. | 742,133 | $2.3B | 10.07% | |
| 113 | VKTXViking Therapeutics, Inc. | 363,980 | $2.3B | 9.98% | |
| 114 | INZYInozyme Pharma, Inc. | 106,999 | $2.1B | 9.19% | |
| 115 | —Molecular Templates, Inc. | 133,833 | $1.7B | 7.32% | |
| 116 | —Affimed N.V. | 164,605 | $1.3B | 5.64% | |
| 117 | OYSTOyster Point Pharma, Inc. | 61,424 | $1.1B | 4.87% | |
| 118 | LPTXEURLeap Therapeutics, Inc. | 559,705 | $1.1B | 4.61% | |
| 119 | —Bellicum Pharmaceuticals, Inc. | 249,123 | $937.0M | 4.06% | |
| 120 | GLPGGalapagos NV | 11,180 | $862.0M | 3.74% | |
| 121 | KZRKezar Life Sciences, Inc. | 139,676 | $832.0M | 3.61% | |
| 122 | —Adamas Pharmaceuticals, Inc. | 147,996 | $710.0M | 3.08% | |
| 123 | GLMDGalmed Pharmaceuticals Ltd. | 184,927 | $634.0M | 2.75% | |
| 124 | IFRXInflarx N.V. | 138,040 | $538.0M | 2.33% | |
| 125 | —Frequency Therapeutics, Inc. | 55,555 | $528.0M | 2.29% | |
| 126 | GNFTYGenfit SA | 14,720 | $68.0M | 0.29% |
PreviousPage 2 of 2